Other Information .
−Removed: During the three months ended September 30, 2023, no director or officer of the Company adopted or terminated a " Rule 10b5-1 trading arrangement" or " non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended March 31, 2024, two of our officers (as defined in Rule 16a-1(f) under the Exchange Act) entered into contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information.
+Added: We refer to these contracts, instructions, and written plans as " Rule 10b5-1 trading plans" and each one as a "Rule 10b5-1 trading plan." We describe the material terms of these trading plans below.
+Added: Ryan Brown entered into and adopted a plan with an effective date of March 7, 2024 and end date of March 15, 2025 , covering 76,508 shares of common stock, 7,574 plus the net shares resulting upon the vesting of future restricted stock units, and 84,082 plus the net shares resulting upon the vesting of future restricted stock units.
+Added: Bilal Arif entered into and adopted a plan with an effective date of March 11, 2024 and end date of March 15, 2025 , covering:
+Added: 7,676 shares of common stock, 5,655 plus the net shares resulting upon the vesting of future restricted stock units, and 13,331 plus the net shares resulting upon the vesting of future restricted stock units.
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.
10 unchanged sentences
Second Amended and Restated Bylaws
−Removed: Certification of the Company’s Principal Executive Officer, Douglas S.
+Added: Sarepta Therapeutics, Inc.
+Added: 2024 Employment Commencement Incentive Plan
+Added: Form of Stock Option Award Agreement under Sarepta Therapeutics, Inc.
+Added: 2024 Employment Commencement Incentive Plan
+Added: Form of Restricted Stock Unit Award Agreement under Sarepta Therapeutics, Inc.
+Added: 2024 Employment Commencement Incentive Plan
+Added: Certification of the Company’s Principal Executive Officer, Douglas S.
Ingram, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of the Company’s Principal Financial and Accounting Officer, Ian M.
+Added: Certification of the Company’s Principal Financial and Accounting Officer, Ian M.
Estepan, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of the Company’s Principal Executive Officer, Douglas S.
+Added: Certification of the Company’s Principal Executive Officer, Douglas S.
Ingram, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of the Company’s Principal Financial and Accounting Officer, Ian M.
+Added: Certification of the Company’s Principal Financial and Accounting Officer, Ian M.
Estepan, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Inline eXtensible Business Reporting Language (XBRL) Instance Document –
−Removed: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
+Added: Inline eXtensible Business Reporting Language (XBRL) Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
Inline XBRL Taxonomy Extension Schema Document.
5 unchanged sentences
Indicates management contract or compensatory plan, contract or arrangement.
−Removed: * Certain identified information has been excluded from the exhibit.
+Added: * Identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
** The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filings of Sarepta Therapeutics, Inc.
2 unchanged sentences
SAREPTA THERAPEUTICS, INC.
−Removed: November 1, 2023
/s/ DOUGLAS S.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 1, 2023
Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.